Sight Sciences, Inc. (SGHT)
SGHTNASDAQ-GSMedical/Dental Instruments
$11.01
+0.9300 (+9.23%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $611.92m
- P/E
- –
- EPS, last 4 quarters
- $-0.4400
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.38 to $10.31
- Average volume
- 301.6k
- Previous close
- $10.08
Analysts
5 coveringBuy4 buy, 1 hold, 0 sell
Targets a year out average $12.00, +9.0% from here
Earnings
next estimate $-0.1000Next report
Dec 2025
+46.7%
Mar 2026
+15.8%
Jun 2026
+46.7%
Sep 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $20.39m | $19.70m | $23.39m | $24.92m |
| Gross profit | $17.79m | $16.98m | $21.37m | $21.42m |
| Operating income | -$3.67m | -$12.41m | -$3.89m | -$6.13m |
| Net income | -$4.16m | -$12.98m | -$4.45m | -$6.81m |
Last four quarters: revenue $88.39m, margin -32.1%, free cash flow -$16.91m
News
8 latest- Sight Sciences Consensus Price Target Raised 10.14% to $11.07Fintel · 18 hours ago
- Sight Sciences (SGHT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- What Sight Sciences (SGHT) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks · 5 days ago
- Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue EstimatesZacks · 5 days ago
- Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?Zacks · Oct 28, 2026
- HC Wainwright & Co. Initiates Coverage of Sight Sciences with BuyFintel · Oct 15, 2026
- Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT RTTNews · Sep 30, 2026
The company
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI Surgical System is an implant-free, minimally invasive glaucoma surgery technology indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- sightsciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.